1 day-3.25%
1 week-8.02%
Current month-6.88%
1 month+7.19%
3 months+99.73%
6 months+112.25%
1 week 147.5
Extreme 147.5
165.5
1 month 134
Extreme 134
185
Current year 37.55
Extreme 37.55
185
1 year 37.55
Extreme 37.55
185
3 years 37.55
Extreme 37.55
185
5 years 37.55
Extreme 37.55
185
10 years 37.55
Extreme 37.55
185
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 13/01/2017
Chief Executive Officer - 13/01/2017
Director of Finance/CFO - 23/09/2019
Director TitleAgeSince
Director/Board Member 52 25/07/2019
Chairman - 13/01/2017
Director/Board Member - 23/10/2025
Change 5-day change 1-year change 3-year change Capi.($)
-3.25%-8.02% - - 649M
+4.16%+3.04%+49.37%+94.17% 74.16B
-0.37%-3.88%+19.75%+78.35% 57.39B
+1.63%+0.98%+3.83%+38.21% 47.64B
+0.50%+2.94%+345.86%+722.17% 44.29B
+3.05%-1.80%+29.79%+34.51% 42.5B
+1.00%-1.46%+4.97%+111.90% 40.71B
-0.54%+2.93%+9.31%+54.06% 30.97B
+1.56%+4.53%+31.34%+26.92% 28.53B
+0.76%-1.45%-7.15%-11.12% 24.34B
Average +0.83%-1.30%+54.12%+127.69% 39.12B
Weighted average by Cap. +1.51%-0.85%+58.31%+136.94%

Financials

2024 2025
Net sales 803K 25.29K 22.56K 21.02K 19.13K 36.03K 2.44M 36.29K 254K 98.82K 1.24M 94.95K 92.9K 4M 50.29M 1.58M 1.41M 1.32M 1.2M 2.26M 153M 2.27M 15.91M 6.19M 77.86M 5.95M 5.82M 250M
Net income -440M -13.87M -12.37M -11.53M -10.49M -19.75M -1.34B -19.9M -139M -54.19M -682M -52.06M -50.94M -2.19B -1.11B -34.85M -31.09M -28.97M -26.36M -49.64M -3.36B -50.01M -350M -136M -1.71B -131M -128M -5.51B
Net Debt - -
Logo Elixiron Immunotherapeutics (Cayman) Limited
Elixiron Immunotherapeutics Cayman Ltd is an investment holding company located in Taiwan, focusing on developing innovative precision immunotherapy drugs for multiple diseases. The Company operates as a new drug research and development enterprise, with products currently in clinical development. Its pipeline is centered on innovative drug development, covering neurodegenerative disorders, immune-related diseases, and oncology. The main clinical-stage candidates are EI-1071 (Enrupatinib) and EI-001 (Indemakitug). EI-1071 (Enrupatinib) is a proprietary small-molecule drug targeting neurodegenerative diseases, with Alzheimer’s disease as its primary indication, currently in Phase II clinical trials. EI-001 (Indemakitug) is an anti-IFNy monoclonal antibody designed for precise immunomodulation in autoimmune diseases.
Employees
-
Date Price Change Volume
05/10/26 TWD 149.00 -3.25% 1,052,337
02/10/26 TWD 154.00 -0.96% 686,154
01/10/26 TWD 155.50 -2.81% 1,118,307
30/09/26 TWD 160.00 -0.93% 786,671
  1. Stock Market
  2. Stocks
  3. 7871 Stock